Journals / MN Oftalmoloji / 2000 / Cilt: 7 - Sayı: 2

Lipoprotein (A) as a risk factor for disease activity and thrombotic complications of Behçet's disease

Behçet olgularında hastalık aktivitesi ve trombotik komplikasyonlar için risk faktörü olarak lipoprotein (a)

Pages
103–106
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To be able to say that high plasma Lp(a) concentrations might be a risk factor for the thrombotic complications in patients with Behçet's Disease, the same measurements should be done in large series during the thrombotic complications are in active and inactive periods and then compared.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE: To evaluate plasma concentrations of lipoprotein (a) [Lp (a)] as a risk factor for disease activity and thrombotic complîcations <rt Behcet's disease, METHODS: Thirty patients with Behçet's disease (8 active, 22 inactive) as study group and 30 normal subjects as control group were included in this study.
📊
Key Findings & Data:The disease activity was evaluated by clinical manifestations such as oral aphthous lesions, genital ulcerations, uveitis and vasculitis, and laboratory investigations such as leucocyte count, Lp (a), C Reactive Protein, compleman C3 and compleman C4 concentrations.
💡
Conclusion & Impact:To be able to say that high plasma Lp(a) concentrations might be a risk factor for the thrombotic complications in patients with Behçet's Disease, the same measurements should be done in large series during the thrombotic complications are in active and inactive periods and then compared.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lipoprotein(a) · Akut faz proteinleri · Akut faz reaksiyonu

Abstract

PURPOSE: To evaluate plasma concentrations of lipoprotein (a) [Lp (a)] as a risk factor for disease activity and thrombotic complîcations <rt Behcet's disease, METHODS: Thirty patients with Behçet's disease (8 active, 22 inactive) as study group and 30 normal subjects as control group were included in this study. Seven patients of inactive Behçet's disease group had the medical history of thrombotic complications. The disease activity was evaluated by clinical manifestations such as oral aphthous lesions, genital ulcerations, uveitis and vasculitis, and laboratory investigations such as leucocyte count, Lp (a), C Reactive Protein, compleman C3 and compleman C4 concentrations. RESULTS: Plasma Lp (a) and other acute phase reactant concentrations were significantly higher in the study group than in the control group (p<0.01). These concentrations were also higher during the active period of the disease than during the inactive period of the disease (p<0.01). Lp (a) concentrations showed significant correlation with concentrations of other acute phase reactans. There was no significant statistical difference between the patients with and without thrombotic complications for any of these measurements (p>0.05). CONCLUSION: The correlation between the Lp (a) and other acute phase reactan concentrations leads us to suggest that high plasma levels of Lp (a) might be a risk factor for the disease activity of Behçet's disease. To be able to say that high plasma Lp(a) concentrations might be a risk factor for the thrombotic complications in patients with Behçet's Disease, the same measurements should be done in large series during the thrombotic complications are in active and inactive periods and then compared.

Özet

AMAÇ; Behçet olgularında, hastalık aktivitesi ve trombotik komplikasyonlar için risk faktörü olarak lipoprotein(a) [Lp(a)] plazma konsantrasyonlarının değerlendirilmesi METOD: Çalışma grubu 30 Behçet Hastasından (8 aktif, 22 inaktif), kontrol grubu 30 sağlıklı kişiden oluşturuldu. İnaktif Behçet olgularının 7'sinde geçirilmiş trombotik komplikasyon mevcuttu. Hastalık aktivitesi oral aft, genital ülserasyon, üveit ve vaskülit gibi klinik bulguların yanı sıra Lp (a), lökosit, C Reaktif Protein, kompleman C3, kompleman C4 gibi akut faz reaktanları da değerlendirilerek belirlendi. BULGULAR: Plazma Lp(a) ve diğer akut faz reaklanlarının konsantrasyonlarında, kontrol grubuna göre çalışma grubundaki yükseklik istatistiksel olarak da anlamlı bulunmuştur (p 0.05). SONUÇ: Lp (a) düzeylerindeki artışın diğer aktif faz reaktanları ile korele olması, Lp (a)'nın yüksek plazma konsantrasyonlarının hastalık aktivitesi için bir risk faktörü olabileceğini düşündürmektedir. Yüksek Lp (a) düzeyinin, trombotik komplikasyonların gelişiminde bir risk faktörü olduğunu söyleyebilmek için daha geniş hasta gruplarında, trombotik komplikasyonlar aktif ve inaktif iken yapılan ölçümlerin karşılaştırılması gerektiği kanısındayız.

🔖

Cite This Article

GÜRBÜZ, Ö., ÖZDEMİR, Y., BİNGÖL, S., KURAL, G. (2000). Lipoprotein (A) as a risk factor for disease activity and thrombotic complications of Behçet's disease. MN Oftalmoloji, Cilt: 7 - Sayı: 2, 103–106. https://ajindex.com/articles/296436

References (18)

  1. Behçet H. Ueber rezideivierende, aphtöse, durch ein virüs verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 46: 414-9
  2. Mamo JG, Bagdassarian A. Behçet's disease: a report of 28 cases. Arch Ophthalmol 1964; 71: 4-14
  3. Wong RC, Ellis CN, Diaz LA. Behçet's disease. Int J Dermatol 1984;23:25-32
  4. O'Duffy JD. Vasculitis in Behçet's Disease. Reum Dis Clin North Am 1990; 16:423-31
  5. Barra C, Beifort R, Abreu MT, Kim MK. Behçet's disease in Brazıl-A review of 49 cases with emphasis on ophthalmic manifestations. Jpn J Ophthalmol 1991; 35: 399-46
  6. George MRK, Chan C, Whitcup SM, Nussenblatt RB. Ocular immunopathology of Behçet's Disease. Surv Ophthalmol 1997; 42: 157-62
  7. Aitchison R, Chu P, Cater DR, Harris RJ. Defective fibronolysis in Behçet's syndrome: significance and possible mechanisms. Ann Rheum Dis 1989; 48: 590-3
  8. Ganzaies-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein (a) compete for the same site. Biochemistry 1989; 28: 2374-7
  9. Kluft C, Michiels JJ, Wijngaards G. Factual ar artificial inhibition of fibrinolysis and the oecurence of venous thrombosis in 3 cases of Behçet's disease. Scand J Haematol 1980; 25: 423-30
  10. Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a spesific inhibitor of tissue psasminogen activator {and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-30
  11. Scanu AM, Fless GM. Lipoprotein (a): Heterogenity and biological relevance. J Clin Invest 1990; 85: 1709-15
  12. Miles LA, Plow EF. Lp(a): An interioper into the fibrinolytic system. Thromb Hemostas 1990; 63: 331-5
  13. Miles LA, Fless GM, Levin EG, Scanu AM. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989; 339: 301-2
  14. Slunga L, Johnson O, Dahlen GH, Erickson S. Lipoprotein (a) and acute phase proteins in acute myocardial infarction. Scan J Clin Lab Invest 1992; 52: 95-101
  15. Noma A, Abe A, Maeda S, Seishima M, Makino K, Yano Y. Lp(a): an acute phase reactant? Chem Phys Lİpids 1994; 67: 411-7
  16. International Study Group For Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1978-80
  17. Berg K. A new serum type system in man-the Lp system. Acta Pathol 1963; 59:369-62
  18. Fiess GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein (a) and lipoprotein (a) derived from the disso